These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
257 related articles for article (PubMed ID: 2680196)
1. Management of blood lipid abnormalities in coronary heart disease patients. Kuo PT Clin Cardiol; 1989 Oct; 12(10):553-60. PubMed ID: 2680196 [TBL] [Abstract][Full Text] [Related]
2. Dyslipidemia and coronary artery disease. Kuo PT Clin Cardiol; 1994 Oct; 17(10):519-27. PubMed ID: 8001298 [TBL] [Abstract][Full Text] [Related]
3. Management of protease inhibitor-associated hyperlipidemia. Penzak SR; Chuck SK Am J Cardiovasc Drugs; 2002; 2(2):91-106. PubMed ID: 14727985 [TBL] [Abstract][Full Text] [Related]
4. Management of lipids in primary and secondary prevention of cardiovascular diseases. Lavie CJ; Gau GT; Squires RW; Kottke BA Mayo Clin Proc; 1988 Jun; 63(6):605-21. PubMed ID: 3287024 [TBL] [Abstract][Full Text] [Related]
5. Perspectives in the treatment of dyslipidemias in the prevention of coronary heart disease. Borgia MC; Medici F Angiology; 1998 May; 49(5):339-48. PubMed ID: 9591525 [TBL] [Abstract][Full Text] [Related]
6. Niacin as a component of combination therapy for dyslipidemia. Miller M Mayo Clin Proc; 2003 Jun; 78(6):735-42. PubMed ID: 12934785 [TBL] [Abstract][Full Text] [Related]
7. Lipids and prevention in coronary care. Betteridge DJ Trans Med Soc Lond; 1994-1995; 111():43-58. PubMed ID: 9156156 [No Abstract] [Full Text] [Related]
11. Treatment of hyperlipidemia in women. Walsh JM; Grady D JAMA; 1995 Oct; 274(14):1152-8. PubMed ID: 7563487 [TBL] [Abstract][Full Text] [Related]
12. Four years' treatment efficacy of patients with severe hyperlipidemia. Lipid lowering drugs versus LDL-apheresis. Schiel R; Bambauer R; Müller UA Int J Artif Organs; 1995 Dec; 18(12):786-93. PubMed ID: 8964646 [TBL] [Abstract][Full Text] [Related]
13. Selection of appropriate type and intensity of lipid-lowering therapy. Tikkanen MJ Curr Opin Lipidol; 1995 Dec; 6(6):360-4. PubMed ID: 8750248 [TBL] [Abstract][Full Text] [Related]
14. Regression of coronary atherosclerosis: an achievable goal? Review of results from recent clinical trials. Waters D; Lespérance J Am J Med; 1991 Jul; 91(1B):10S-17S. PubMed ID: 1867231 [TBL] [Abstract][Full Text] [Related]
15. Pharmacologic treatment of type 2 diabetic dyslipidemia. Moon YS; Kashyap ML Pharmacotherapy; 2004 Dec; 24(12):1692-713. PubMed ID: 15585439 [TBL] [Abstract][Full Text] [Related]
16. Niacin-ER and lovastatin treatment of hypercholesterolemia and mixed dyslipidemia. Yim BT; Chong PH Ann Pharmacother; 2003 Jan; 37(1):106-15. PubMed ID: 12503944 [TBL] [Abstract][Full Text] [Related]
17. Dyslipidemias and the secondary prevention of coronary heart disease. Rosenson RS; Frauenheim WA; Tangney CC Dis Mon; 1994 Aug; 40(8):369-464. PubMed ID: 8050340 [TBL] [Abstract][Full Text] [Related]
18. The triglyceride-high-density lipoprotein axis: an important target of therapy? Szapary PO; Rader DJ Am Heart J; 2004 Aug; 148(2):211-21. PubMed ID: 15308990 [TBL] [Abstract][Full Text] [Related]